AlphaQuest LLC Cuts Stake in Hologic, Inc. (NASDAQ:HOLX)

AlphaQuest LLC trimmed its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 52.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 21,791 shares of the medical equipment provider's stock after selling 24,048 shares during the period. AlphaQuest LLC's holdings in Hologic were worth $1,571,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. General Partner Inc. purchased a new stake in shares of Hologic in the 4th quarter valued at approximately $26,000. Groupama Asset Managment increased its stake in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent research reports. Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Raymond James reaffirmed an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target for the company. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $84.62.

Remove Ads

Hologic Stock Down 0.7 %

Shares of Hologic stock traded down $0.40 during trading hours on Thursday, hitting $60.70. The company had a trading volume of 2,339,023 shares, compared to its average volume of 2,366,857. The company's 50-day moving average is $67.65 and its two-hundred day moving average is $74.94. Hologic, Inc. has a twelve month low of $60.33 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market cap of $13.62 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.